Welcome to our dedicated page for Opgen news (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen stock.
OpGen, Inc. (NASDAQ: OPGN) regularly issues news and regulatory updates that describe its activities in precision medicine, molecular diagnostics, and bioinformatics for infectious disease and antimicrobial resistance. This news page aggregates those disclosures so readers can review how the company presents its business focus, collaborations, financings, and operational changes over time.
Company announcements have covered topics such as research and development collaborations involving antimicrobial resistance panels and genomic surveillance, feature releases for the AREScloud platform, and work related to the Unyvero systems and ARES Technology Platform. OpGen’s releases also discuss financial performance, cash management initiatives, and its own statements about substantial doubt regarding its ability to continue as a going concern, along with potential strategic alternatives it is considering.
Investors and observers can also find information here on equity and financing transactions, including preferred stock financings, warrant inducement agreements, and a securities purchase agreement that allows OpGen to sell common stock to an investor over time. Additional news items describe insolvency proceedings of subsidiaries Curetis GmbH and Ares Genetics GmbH, the sale of their assets by insolvency trustees, and agreements to transfer commercial customer contracts and installed Unyvero systems.
Corporate governance and management changes are another recurring theme in OpGen’s news, including appointments and resignations of directors and executive officers and a 1‑for‑10 reverse stock split intended, according to the company, to support compliance with Nasdaq’s minimum bid price requirement. This page allows readers to follow these developments through the company’s own published statements.
OpGen reported Q3 2021 revenue of approximately $1.24 million, a 17% increase from Q3 2020. The cash balance rose significantly to $25.4 million as of September 30, 2021, bolstered by a $15 million financing completed in October. Key milestones include FDA clearance for the Acuitas AMR Gene Panel, launching AREScloud software, and a new CFO appointment. The net loss narrowed to $6.1 million in Q3 2021 from $7.7 million in Q3 2020. OpGen remains focused on enhancing its commercial operations and future clinical trials.
OpGen, a precision medicine company, announces the appointment of Albert Weber as Chief Financial Officer effective January 1, 2022. Weber brings over 30 years of experience, notably from Epigenomics, enhancing OpGen's financial leadership. With the recent FDA clearance for the Acuitas AMR Gene Panel and other products in the pipeline, Weber aims to contribute to the company's growth. An inducement grant of 210,000 stock options was also announced as part of his compensation.
OpGen, Inc. (Nasdaq: OPGN) has scheduled a Special Meeting of stockholders for December 8, 2021, to vote on increasing its authorized shares from 50 million to 100 million. Additionally, the meeting will seek to lower the stockholder approval requirement for changes to the Company's Amended Certificate of Incorporation to a majority of outstanding shares. Stockholders eligible to vote are those on record as of October 19, 2021. Details are outlined in the Definitive Proxy Statement filed with the SEC on October 29, 2021.
OpGen, Inc. (NASDAQ: OPGN) announced it will report its third quarter 2021 financial results on November 11, 2021, after U.S. market close. A live conference call and audio webcast will start at 4:30 p.m. ET, where management will discuss the financial outcomes and current business activities. The call will be accessible via a U.S. dial-in number and an international dial-in number, with a replay available until November 25, 2021. OpGen focuses on precision medicine and molecular diagnostics to tackle infectious diseases.
OpGen has launched AREScloud, a web application aimed at enhancing the analysis of sequenced clinical isolates for infection control. The platform offers a comprehensive solution that automates data processing from raw sequence to actionable reports, supporting epidemiologists and microbiologists in combating antimicrobial resistance (AMR).
AREScloud includes access to ARESdb, a proprietary database for AMR markers. The application has been validated in clinical studies, successfully predicting antibiograms from genomic data, which is crucial for improving treatment outcomes.
OpGen, Inc. (Nasdaq: OPGN) has successfully closed a registered direct offering, raising $15 million through the issuance of 150,000 shares of convertible preferred stock and warrants for 7,500,000 shares of common stock. The preferred stock is convertible at $2.00 per share, subject to shareholder approval for increasing authorized shares. The funds will support the commercialization of the Acuitas AMR Gene Panel test, further development of the Unyvero platform, debt repayment, and general corporate purposes. The company plans to amend its bylaws to facilitate the offering.
OpGen, Inc. (Nasdaq: OPGN) announced a definitive agreement for a registered direct offering to a single institutional investor. This includes 150,000 shares of convertible preferred stock and warrants for gross proceeds of $15 million. The preferred stock is convertible into 7,500,000 shares of common stock at a price of $2.00 per share after shareholder approval. Proceeds will be used for commercialization of the Acuitas AMR Gene Panel, repayment of debt, and other corporate purposes. The offering is expected to close around October 18, 2021.
OpGen announced FDA 510(k) clearance for the Acuitas® AMR Gene Panel, allowing testing for 28 genetic antimicrobial resistance markers across 26 pathogens. This panel aids clinicians in managing antibiotic-resistant infections and is expected to launch commercially in Q4 2021. The panel provides rapid results, enhancing decision-making in antibiotic treatment, and is considered a vital tool in combatting the severe global threat of drug-resistant bacteria, which cause significant infections and deaths annually.
OpGen, Inc. (Nasdaq: OPGN) reported preliminary Q3 2021 revenue of approximately $1.2 million, a slight increase from $1.1 million in Q3 2020. Cash reserves surged to $25.4 million as of September 30, 2021, compared to $13.4 million at the end of 2020. Key developments include receiving FDA 510(k) clearance for the Acuitas AMR Gene Panel and initiating a clinical trial for Unyvero UTI. The company is also finalizing the appointment of a new CFO and filed a shelf registration for up to $150 million to support future growth.
OpGen has initiated a prospective multicenter clinical trial for its Unyvero Urinary Tract Infection (UTI) Panel, which tests for various pathogens and antimicrobial resistance directly from urine samples. The trial aims to include over 1,500 U.S. patients and evaluate the panel's clinical performance in comparison to standard culture-based testing. Following the study, OpGen intends to submit data to the FDA for clearance. The Unyvero platform previously obtained FDA clearance for other panels, enhancing its market potential in addressing UTIs, a significant public health issue with 3 million cases annually in the U.S.